Your browser does not support iframes.
A Food and Drug Administration advisory panel recommended approval for Onyx Pharmaceuticals Inc.'s (Nasdaq: ONXX) multiple myeloma treatment carfilzomib sending the stock price soaring $19.43 to $64.01.